Canada markets close in 25 minutes
  • S&P/TSX

    +199.44 (+1.00%)
  • S&P 500

    +56.79 (+1.36%)
  • DOW

    +589.14 (+1.77%)

    +0.0070 (+0.87%)

    +1.83 (+2.55%)

    -3,865.17 (-8.81%)
  • CMC Crypto 200

    -66.32 (-7.80%)

    +14.70 (+0.83%)
  • RUSSELL 2000

    +48.03 (+2.15%)
  • 10-Yr Bond

    +0.0340 (+2.34%)

    +99.72 (+0.71%)

    -2.49 (-12.03%)
  • FTSE

    +44.82 (+0.64%)
  • NIKKEI 225

    -953.15 (-3.29%)

    +0.0030 (+0.44%)

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Analysts Just Trimmed Their Revenue Forecasts By 12%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

The latest analyst coverage could presage a bad day for RAPT Therapeutics, Inc. (NASDAQ:RAPT), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative. Investors however, have been notably more optimistic about RAPT Therapeutics recently, with the stock price up a noteworthy 14% to US$20.43 in the past week. With such a sharp increase, it seems brokers may have seen something that is not yet being priced in by the wider market.

Following the downgrade, the current consensus from RAPT Therapeutics' five analysts is for revenues of US$2.9m in 2020 which - if met - would reflect a major 213% increase on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$3.3m in 2020. The consensus view seems to have become more pessimistic on RAPT Therapeutics, noting the measurable cut to revenue estimates in this update.

See our latest analysis for RAPT Therapeutics

NasdaqGM:RAPT Past and Future Earnings June 4th 2020
NasdaqGM:RAPT Past and Future Earnings June 4th 2020

The Bottom Line

The clear low-light was that analysts slashing their revenue forecasts for RAPT Therapeutics this year. Given the stark change in sentiment, we'd understand if investors became more cautious on RAPT Therapeutics after today.

Unsatisfied? At least one of RAPT Therapeutics' five analysts has provided estimates out to 2024, which can be seen for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting